References
- Buhman KK, Smith SJ, Stone SJ, et al. (2002). DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 277:25474–9.
- Cao J, Zhou Y, Peng H, et al. (2011). Targeting Acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1) with small molecule inhibitors for the treatment of metabolic diseases. J Biol Chem 286:41838–51.
- Cases S, Smith SJ, Zheng Y-W, et al. (1998). Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci 95:13018–23.
- Cases S, Stone SJ, Zhou P, et al. (2001). Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 276:38870–6.
- Dayneka NL, Garg V, Jusko WJ. (1993). Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21:457–78.
- Dow RL, Li J-C, Pence MP, et al. (2011). Discovery of PF-04620110, a potent, selective, and orally bioavailable inhibitor of DGAT-1. ACS Med Chem Lett 2:407–12.
- Eliot LA, Foster RT, Jamali F. (1999). Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 16:309–13.
- Enayetallah AE, Ziemek D, Leininger MT, et al. (2011). Modeling the mechanism of action of a DGAT1 inhibitor using a causal reasoning platform. PLoS One 6:e27009.
- Faltaos DW, Urien S, Carreau V, et al. (2006). Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol 20:321–30.
- Farnier M, Davignon J. (1998). Current and future treatment of hyperlipidemia: the role of statins. Am J Cardiol 82:3J–10J.
- Gibbons G, Wiggins D, Brown A-M, Hebbachi A-M. 2004. Synthesis and function of hepatic very-low-density lipoprotein. Biochem Soc T 32:59–64.
- Kim JH, Sen Ś, Avery CS, et al. (2001). Genetic analysis of a new mouse model for non-insulin-dependent diabetes. Genomics 74:273–86.
- Kim JH, Stewart TP, Soltani-Bejnood M, et al. (2006). Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice. J Endocrinol 191:437–46.
- Kim JH, Stewart TP, Zhang W, et al. (2005). Type 2 diabetes mouse model TallyHo carries an obesity gene on chromosome 6 that exaggerates dietary obesity. Physiol Genom 22:171–81.
- King AJ, Segreti JA, Larson KJ, et al. (2009). Diacylglycerol acyltransferase 1 inhibition lowers serum triglycerides in the Zucker fatty rat and the hyperlipidemic hamster. J Pharmacol Exp Ther 330:526–31.
- Maron DJ, Fazio S, Linton MF. (2000). Current perspectives on statins. Circulation 101:207–13.
- Meyers CD, Kamanna VS, Kashyap ML. (2004). Niacin therapy in atherosclerosis. Curr Opin Lipidol 15:659–65.
- Michaelis UR, Xia N, Barbosa-Sicard E, et al. (2008). Role of cytochrome P450 2C epoxygenases in hypoxia-induced cell migration and angiogenesis in retinal endothelial cells. Invest Ophthalmol Vis Sci 49:1242–7.
- Rhee SD, Jeong WH, Sung YY, et al. (2004). Characteristics of the newly established diabetic model mice, TallyHo. J Korean Diabetes Assoc 28:177–86.
- Ross R, Harker L. (1976). Hyperlipidemia and atherosclerosis. Science 193:1094–100.
- Shayeganpour A, Jun AS, Brocks DR. (2005). Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 26:249–57.
- Snow V, Aronson MD, Hornbake ER, et al. (2004). Lipid control in the management of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann Intern Med 140:644–9.
- Streeper RS, Koliwad SK, Villanueva CJ, Farese RV. (2006). Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin. Am J Physiol-Endocrinol Metabol 291:E388–E94.
- Subauste A, Burant CF. (2003). DGAT: novel therapeutic target for obesity and type 2 diabetes mellitus. Curr Drug Targets Immune Endocr Metabol Disord 3:263–70.
- Van Schaick EA, De Greef HJ, Ijzerman AP, Danhof M. (1997). Physiological indirect effect modeling of the antilipolytic effects of adenosine A 1-receptor agonists. J Pharmacokinet Biopharm 25:673–94.
- Wojcicki J, Gornik W, Pawlik A, et al. (1996). Comparative pharmacokinetics of theophylline in rabbits and in humans with hyperlipidemia. Pulmon Pharmacol 9:175–8.
- Zhang Y, Ren J. (2011). Role of cardiac steatosis and lipotoxicity in obesity cardiomyopathy. Hypertension 57:148–50.
- Zhao G, Souers AJ, Voorbach M, et al. (2008). Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor. J Med Chem 51:380.